目的：比较康柏西普不同给药方案治疗病理性近视脉络膜新生血管(PM-CNV)的疗效。

方法：前瞻性临床研究。选取2019-01/2022-01在我院确诊为PM-CNV的患者42例42眼，根据初始治疗方案分为1+PRN组和3+PRN组，其中1+PRN组患者20例20眼初始1 mo玻璃体腔注射给药1次后按需给药(PRN)； 3+PRN组患者22例22眼初始3 mo每月玻璃体腔注射给药1次后PRN。初始治疗后随访12 mo，比较两组患者最佳矫正视力(BCVA)、中心凹视网膜厚度(CMT)、CNV面积及注药次数。

结果：与治疗前相比，治疗后1、3、6、12 mo，两组患者视力均改善，CMT均降低，CNV面积均减小(P<0.01)，但两组患者BCVA、CMT、CNV面积均无组间差异(P>0.05)。1+PRN组患者平均注药次数明显少于3+PRN组\〖2(1，3)次 vs 3(3，4)次，P<0.05\〗，但初始治疗后再注药次数多于3+PRN组\〖1(0，2)次 vs 0(0，1)次，P<0.05\〗。

结论：康柏西普两种方案均可安全有效治疗PM-CNV，改善BCVA，降低CMT，减小CNV面积，1+PRN治疗方案总注药次数更少，而3+PRN治疗方案再注药次数更少。

METHODS: Prospective clinical study. Totally 42 patients(42 eyes)who were diagnosed with pathological myopic CNV in our hospital from January 2019 to January 2022 were selected in the study. According to two different initial dosing regimens, the patients were divided into 1+pro re nata(PRN)group, with 20 patients(20 eyes), and 3+PRN group with 22 patients(22 eyes). The patients in the 1+PRN group were given one intravitreal injection and then given PRN, the patients in the 3+PRN group were given intravitreal injection once a month for 3 mo and then given PRN. Followed-up for 12 mo after initial treatment, the best corrected visual acuity(BCVA), central macular thickness(CMT), CNV area and injection times were compared between the two groups.

RESULTS: The BCVA was improved, CMT was decreased, and CNV area was reduced at 1, 3, 6, and 12 mo after the initial treatment(P<0.01). However, there was no statistically significant difference in BCVA, CMT and CNV area between two groups(P>0.05). The average injection in the 1+PRN group was significantly less than that of the 3+PRN group \〖2(1, 3)times vs 3(3, 4)times, P<0.05\〗, but the average reinjection in the 1+PRN group was more than that of the 3+PRN group \〖1(0, 2)times vs 0(0, 1)times, P<0.05\〗.

CONCLUSION: Two regimens were both safe and effective in the treatment of pathological myopic CNV by Conbercept, which can improve BCVA, decrease CMT, and reduce CNV area, with less total times of injection in the 1+PRN regimen, and less times of reinjection in the 3+PRN regimen.